|Bid||179.900 x 0|
|Ask||180.000 x 0|
|Day's Range||179.400 - 189.600|
|52 Week Range||77.250 - 209.200|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.56|
Vir Biotechnology, Inc. (VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (BIIB) based on the letter of intent that the companies announced in March. Under the agreement Biogen will perform process development activities and specified manufacturing and process transfer services to enable commercial supply of Vir’s SARS-CoV-2 monoclonal antibodies.
SAN FRANCISCO, May 12, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...